Lactic Acid Bacteria (DK128) Have Protective Immunity against Influenza A Virus

Lactic acid bacteria used as probiotics to improve stomach digestive health can also offer protection against other subtypes of flu An virus, resulting from about reduced weight after virus infection and lower amounts of virus replication in the lungs, as indicated by a study led by Georgia State University. Influenza virus can cause severe respiratory disease in individuals.

In spite of the fact that vaccines for seasonal influenza viruses are readily available, influenza virus infections make three five million dangerous illnesses and 250,000 to 500,000 deaths across the world during epidemics. Pandemic episodes and air transmission can quickly cause severe disease and claim many more human lives around the world. This happens in light because present vaccines are powerful just when vaccine strains and circulating influenza viruses are very much matched.

Lactic Acid Bacteria (DK128)

Influenza A virus has a wide range of subtypes in view of hemagglutinin (HA) and neuraminidase (NA) proteins on the surface of the virus. There are 18 different HA and 11 different NA subtype molecules identified, which demonstrates numerous HA and NA influenza virus combinations.

Accordingly, it’s essential to find ways to give broad protection against influenza viruses, regardless of the virus strain. Fermented vegetables and dairy products contain a variety of lactic acid bacteria, which have a number of health advantages notwithstanding being used as probiotics. Against bacterial infectious diseases, such as Streptococcus pneumoniae researchers have discovered some lactic acid bacteria strains which give partial protection, and in addition cold and influenza viruses.

This examination researched from fermented vegetables, the antiviral protective effects of a heat-killed strain of lactic acid bacteria, Lactobacillus casei (DK128), a promising probiotic isolated, on influenza viruses. Mice showed a variety of immune responses with protection against influenza virus when pretreated with DK128 intranasally and infected with influenza A virus, including an increase in the alveolar macrophage cells in the lungs and airways, early induction of virus particular antibodies and decreased levels of pro-inflammatory cytokines and innate immune cells. Against secondary influenza A virus the mice also developed immunity. The discoveries are published in the journal Scientific Reports.

Dr. Sang-Moo Kang, lead author of the study and professor in the Institute for Biomedical Sciences at Georgia State said, “We found that pretreating the mice with heat-killed Lactobacillus casei DK128 bacteria made them protected them against weight reduction and mortality and resistant to lethal primary and secondary influenza A virus infection”.

“Our outcomes are highly significant because mice pretreated with DK128 had 100% survival and prevention of weight reduction. Additionally, the strain of lactic acid bacteria equipped mice with cross-protective immunity against secondary lethal infection with influenza virus. Protection against influenza virus infection was not particular to a specific strain of influenza.

“Our examination gives evidence that heat killed acid bacteria could potentially be controlled by means of a nasal spray as a prophylactic drug against non- specific influenza virus infections.”

The scientists with heat-killed DK128 pretreated mice intranasally and then infected them with a lethal dose of influenza A infection, subtype H3N2 or H1N1. Mice indicated 10 to 12% weight reduction when pretreated with a low dose of DK128, but survived the lethal infection of H3N2 or H1N1 virus. Interestingly, mice pretreated with a higher dose of heat-killed DK128 did not indicate weight reduction. Control mice, which were not pretreated with DK128, indicated severe weight reduction by days eight and nine of the infection and these mice died.

Mice that received heat-killed lactic acid bacteria (DK128) before to infection had around 18 times less influenza virus in their lungs compared with control mice. Later, by infecting pretreated mice with a different influenza A subtype from their primary virus infection the scientists tested protection against secondary influenza virus infection.

Mice were exposed to the secondary virus infection to H1N1 or rgH5N1. The research outcomes suggest that pretreatment with lactic acid bacteria, particularly DK128, equips mice with the ability to have protective immunity against a wide range of primary and secondary influenza A virus infections.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

five × three =